Bronchodilator reversibility in Australian adults with chronic obstructive pulmonary disease

Internal Medicine Journal

Volumn 33, Issue 12, 2003, Pages 572-577

  Reid, D W ^a   Soltani, A ^a   Johns, D P ^b   Bish, R ^a   Williams, T J ^a   Burns, G P ^a   Walters, E H ^b  

^a ALFRED HOSPITAL   (Australia)

^b UNIVERSITY OF TASMANIA   (Australia)

Author keywords

Bronchodilator reversibility; COPD; Inhaled corticosteroids

Indexed keywords

BRONCHODILATING AGENT; CORTICOSTEROID; SALBUTAMOL;

ADULT; AGED; AIRFLOW; ARTICLE; ASTHMA; AUSTRALIA; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; CONTROLLED STUDY; DISEASE SEVERITY; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; NEW ZEALAND; PRACTICE GUIDELINE; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ASTHMA; BRONCHODILATOR AGENTS; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX; SMOKING;

EID: 1642512327     PISSN: 14440903     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2003.00485.x     Document Type: Article

References (29)

1. Izumi T. Definition of chronic obstructive pulmonary disease. Nippon Rinsho 1999; 57: 1937-44.
2. Celli BR. ATS standards for the optimal management of chronic obstructive pulmonary disease. Respirology 1997; 2: S1-4.
3. Petty TL. Definitions in chronic obstructive pulmonary disease. Clin Chest Med 1990; 11: 363-73.
4. Matthys H. Definition and assessment of asthma. Lung 1990; 168: 51-6.
5. Teculescu D. Clear definitions of chronic bronchopulmonary diseases: a necessity for practice, teaching and research in pneumology. Rev Pneumol Clin 1990; 46: 194-9.
6. Snider GL. Chronic obstructive pulmonary disease: a definition and implications of structural determinants of airflow obstruction for epidemiology. Am Rev Respir Dis 1989; 140: S3-8.
7. Mathers CD, Vos ET, Stevenson CE, Begg SJ. The burden of disease and injury in Australia. Bull World Health Organ 2001; 79: 1076-84.
8. Cooreman J, Thom TJ, Higgins MW. Mortality from chronic obstructive pulmonary diseases and asthma in France, 1969-83. Comparisons with the United States and Canada. Chest 1990; 97: 213-9.
9. Higgins MW. Chronic airways disease in the United States: trends and determinants. Chest 1989; 96: 328S-334S.
10. Higgins MW, Keller JB. Trends in COPD morbidity and mortality in Tecumseh, Michigan. Am Rev Respir Dis 1989; 140: S42-8.
11. Higgins M. Epidemiology of COPD: state of the art. Chest 1984; 85: 3S-8S.
12. Abramson M, Matheson M, Wharton C, Sim M, Walters EH. Prevalence of COPD amongst middle aged and older adults. Respirology 2001; 6: A12.
13. Turato G, Zuin R, Saetta M. Pathogenesis and pathology of COPD. Respiration 2001; 68: 117-28.
14. Saetta M, Turato G, Zuin R. Structural basis for airflow limitation in chronic obstructive pulmonary disease. Sarcoidosis Vasc Diffuse Lung Dis 2000; 17: 239-45.
15. Tiddens HA, Hofhuis W, Bogaard JM, Hopp WC, van der Mark TW, de Boer WJ et al. Compliance, hysteresis, and collapsibility of human small airways. Am J Respir Crit Care Med 1999; 160: 1110-8.
16. Fletcher C, Peto R. Natural history of chronic respiratory tract obstruction. Bull Int Union Tuberc 1978; 53: 79-87.
17. British Thoracic Society. British Thoracic Society guidelines for the management of chronic obstructive pulmonary disease. The COPD Guidelines Group of the Standards of Care Committee of the BTS. Thorax 1997; 52: S1-28.
18. Siafakas NM, Vermeire P, Pride NB, Paoletti P, Gibson J, Howarth P et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. Eur Respir J 1995; 8: 1398-420.
19. Burge PS. EUROSCOP, ISOLDE and the Copenhagen city lung study. Thorax 1999; 54: 287-8.
20. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. Br Med J 2000; 320: 1297-303.
21. Pauwels RA, Lofdahl CG, Laitinen LA, Schouten JP, Postma DS, Pride NB et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society study on chronic obstructive pulmonary disease. N Engl J Med 1999; 340: 1948-53.
22. Vestbo J, Sorensen T, Lange P, Brix A, Torre P, Viskum K. Long-term effect of inhaled budesonide in mild and moderate chronic pulmonary disease: a randomised controlled trial. Lancet 1999; 353: 1819-23.
23. Quadrelli SA, Roncoroni AJ, Montiel GC. Evaluation of bronchodilator response in patients with airway obstruction. Respir Med 1999; 93: 630-6.
24. Borg B, Side E, Johns DP. The Assessment and Interpretation of Airflow Limitation Using Bronchodilators: Current Practice in Laboratories in Australia and New Zealand. Proceedings of the Australia and New Zealand Society of Respiratory Science Annual Scientific Meeting; 2001 March 16-19; Brisbane, Australia. Adelaide: Australia and New Zealand Society of Respiratory Science; 2001.
25. American Thoracic Society. Standardisation of spirometry 1994 update. Am J Respir Crit Care Med 1995; 152: 1107-36.
26. Vermeire PA, Pride NB. A 'splitting' look at chronic nonspecific lung disease (CNSLD): common features but diverse pathogenesis. Eur Respir J 1991; 4: 490-6.
27. Eliasson O, Degraff AC Jr. The use of criteria for reversibility and obstruction to define patient groups for bronchodilator trials. Influence of clinical diagnosis, spirometric, and anthropometric variables. Am Rev Respir Dis 1985; 132: 858-64.
28. Maisel JC, Silvers GW, Mitchell RS, Petty TL. Bronchial atrophy and dynamic expiratory collapse. Am Rev Respir Dis 1968; 98: 98897.
29. Maisel JC, Silvers GW, George MS, Dart GA, Petty TL, Mitchell RS. The significance of bronchial atrophy. Am J Pathol 1972; 67: 371-86.